Non-invasive bio-electromagnetic monitoring of cerebrovascular function: a novel conductivity reactivity index (CRx) for optimal cerebral perfusion pressure in acute brain injury models.

IF 4.3 3区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Frontiers in Bioengineering and Biotechnology Pub Date : 2025-07-09 eCollection Date: 2025-01-01 DOI:10.3389/fbioe.2025.1564510

Jia Xu, Haochen Li, Feng Wang, Lian Yan, Gui Jin, Mingsheng Chen, Gen Li, Mingxin Qin

{"title":"Non-invasive bio-electromagnetic monitoring of cerebrovascular function: a novel conductivity reactivity index (CRx) for optimal cerebral perfusion pressure in acute brain injury models.","authors":"Jia Xu, Haochen Li, Feng Wang, Lian Yan, Gui Jin, Mingsheng Chen, Gen Li, Mingxin Qin","doi":"10.3389/fbioe.2025.1564510","DOIUrl":null,"url":null,"abstract":"Introduction: The pressure reactivity index (PRx) is a key predictor of cerebrovascular function, widely used to guide and optimize therapeutic strategies in patients with acute brain injury. This study investigates a non-invasive bio-electromagnetic technique for monitoring and maintaining cerebrovascular function in a rabbit model of acute brain injury.Methods: A coaxial parallel double-coil sensor was designed to detect changes in intracranial electromagnetic properties, measured as magnetic induction phase shifts (MIPS), which reflect cerebral blood volume fluctuations. A cerebrovascular function monitoring platform was constructed with this sensor, a vector network analyzer, a LabVIEW software platform, and a physiological signal acquisition device to record the MIPS and arterial blood pressure (ABP). In the animal experiment, a novel cerebrovascular function index Conductivity Reactivity index (CRx), established with MIPS and ABP, was to assess optimal cerebral blood perfusion pressure (CPP) for maintaining the cerebrovascular function in four gradients of CPP in acute brain injury model.Results: The results found that the CRx (-0.072 ± 0.203) was a significant negative correlation with the PRx (0.223 ± 0.203) (r = -0.447, P = 0.003). Under the optimal CPP determined by the CPP-CRx curve, the mean CRx (0.104 ± 0.170) indicated normal cerebrovascular function, which was significantly different from the other states (CRx = -0.127 ± 0.061, p = 0.009).Discussion: The study demonstrated that CRx has potential to reflect cerebrovascular function dynamics and assess optimal CPP, demonstrating the potential of bio-electromagnetic technology as a noninvasive indicator for monitoring cerebrovascular function.","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1564510"},"PeriodicalIF":4.3000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283717/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1564510","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The pressure reactivity index (PRx) is a key predictor of cerebrovascular function, widely used to guide and optimize therapeutic strategies in patients with acute brain injury. This study investigates a non-invasive bio-electromagnetic technique for monitoring and maintaining cerebrovascular function in a rabbit model of acute brain injury.

Methods: A coaxial parallel double-coil sensor was designed to detect changes in intracranial electromagnetic properties, measured as magnetic induction phase shifts (MIPS), which reflect cerebral blood volume fluctuations. A cerebrovascular function monitoring platform was constructed with this sensor, a vector network analyzer, a LabVIEW software platform, and a physiological signal acquisition device to record the MIPS and arterial blood pressure (ABP). In the animal experiment, a novel cerebrovascular function index Conductivity Reactivity index (CRx), established with MIPS and ABP, was to assess optimal cerebral blood perfusion pressure (CPP) for maintaining the cerebrovascular function in four gradients of CPP in acute brain injury model.

Results: The results found that the CRx (-0.072 ± 0.203) was a significant negative correlation with the PRx (0.223 ± 0.203) (r = -0.447, P = 0.003). Under the optimal CPP determined by the CPP-CRx curve, the mean CRx (0.104 ± 0.170) indicated normal cerebrovascular function, which was significantly different from the other states (CRx = -0.127 ± 0.061, p = 0.009).

Discussion: The study demonstrated that CRx has potential to reflect cerebrovascular function dynamics and assess optimal CPP, demonstrating the potential of bio-electromagnetic technology as a noninvasive indicator for monitoring cerebrovascular function.

查看原文本刊更多论文

无创生物电磁监测脑血管功能：一种用于急性脑损伤模型最佳脑灌注压的新型电导反应性指数（CRx）。

压力反应性指数（PRx）是脑血管功能的重要预测指标，广泛用于指导和优化急性脑损伤患者的治疗策略。本研究探讨了一种无创生物电磁技术监测和维持兔急性脑损伤模型的脑血管功能。方法：设计同轴平行双线圈传感器，检测颅内电磁特性的变化，测量磁感应相移（MIPS），反映脑血容量的波动。利用该传感器、矢量网络分析仪、LabVIEW软件平台和生理信号采集装置构建脑血管功能监测平台，记录MIPS和动脉血压（ABP）。在动物实验中，采用MIPS和ABP建立新的脑血管功能指标传导反应指数（CRx），评估急性脑损伤模型在CPP四个梯度下维持脑血管功能的最佳脑血流灌注压（CPP）。结果：CRx（-0.072±0.203）与PRx（0.223±0.203）呈显著负相关（r = -0.447, P = 0.003）。在CPP-CRx曲线确定的最佳CPP下，平均CRx（0.104±0.170）表示脑血管功能正常，与其他状态（CRx = -0.127±0.061,p = 0.009）差异有统计学意义。讨论：本研究表明，CRx具有反映脑血管功能动态和评估最佳CPP的潜力，表明生物电磁技术作为监测脑血管功能的无创指标的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Bioengineering and Biotechnology Chemical Engineering-Bioengineering

CiteScore

8.30

自引率

5.30%

发文量

2270

审稿时长

12 weeks

期刊介绍： The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs. In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.